Rice Hall James & Associates LLC Has $27.53 Million Stake in Viridian Therapeutics, Inc. $VRDN

Rice Hall James & Associates LLC boosted its holdings in shares of Viridian Therapeutics, Inc. (NASDAQ:VRDN) by 3.9% in the fourth quarter, HoldingsChannel reports. The firm owned 884,532 shares of the company’s stock after acquiring an additional 32,869 shares during the period. Viridian Therapeutics makes up 1.5% of Rice Hall James & Associates LLC’s portfolio, making the stock its 16th biggest position. Rice Hall James & Associates LLC’s holdings in Viridian Therapeutics were worth $27,527,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently bought and sold shares of VRDN. Aster Capital Management DIFC Ltd acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at $35,000. ANTIPODES PARTNERS Ltd acquired a new stake in Viridian Therapeutics during the 4th quarter valued at $36,000. Larson Financial Group LLC acquired a new stake in Viridian Therapeutics during the 3rd quarter valued at $52,000. US Bancorp DE increased its holdings in Viridian Therapeutics by 23.2% during the 3rd quarter. US Bancorp DE now owns 2,457 shares of the company’s stock valued at $53,000 after purchasing an additional 463 shares in the last quarter. Finally, Clearstead Advisors LLC increased its holdings in Viridian Therapeutics by 3,868.3% during the 3rd quarter. Clearstead Advisors LLC now owns 5,000 shares of the company’s stock valued at $108,000 after purchasing an additional 4,874 shares in the last quarter.

Insider Activity

In related news, Director Fairmount Funds Management Llc purchased 1,176,470 shares of Viridian Therapeutics stock in a transaction dated Monday, May 11th. The shares were acquired at an average cost of $17.00 per share, for a total transaction of $19,999,990.00. Following the transaction, the director directly owned 5,090,928 shares of the company’s stock, valued at approximately $86,545,776. This trade represents a 30.05% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. 2.40% of the stock is owned by corporate insiders.

Viridian Therapeutics Stock Down 0.3%

NASDAQ VRDN opened at $16.30 on Tuesday. The stock has a fifty day moving average of $15.91 and a 200-day moving average of $25.14. The stock has a market capitalization of $1.68 billion, a P/E ratio of -4.91 and a beta of 0.90. Viridian Therapeutics, Inc. has a 52 week low of $13.18 and a 52 week high of $34.29. The company has a debt-to-equity ratio of 0.10, a quick ratio of 15.15 and a current ratio of 15.15.

Viridian Therapeutics (NASDAQ:VRDN) last released its earnings results on Tuesday, May 5th. The company reported ($0.90) EPS for the quarter, beating the consensus estimate of ($1.06) by $0.16. The company had revenue of $0.14 million during the quarter, compared to analysts’ expectations of $0.04 million. Viridian Therapeutics had a negative return on equity of 80.19% and a negative net margin of 490.31%.The business’s revenue for the quarter was up 95.8% on a year-over-year basis. During the same period last year, the firm earned ($0.87) EPS. On average, equities research analysts forecast that Viridian Therapeutics, Inc. will post -3.87 EPS for the current year.

Analysts Set New Price Targets

A number of equities research analysts recently weighed in on VRDN shares. HC Wainwright dropped their price target on Viridian Therapeutics from $34.00 to $22.00 and set a “buy” rating for the company in a report on Tuesday, March 31st. The Goldman Sachs Group lowered their target price on Viridian Therapeutics from $36.00 to $31.00 and set a “buy” rating for the company in a research note on Tuesday, April 7th. Truist Financial lowered their target price on Viridian Therapeutics from $36.00 to $33.00 and set a “buy” rating for the company in a research note on Tuesday, April 21st. Wedbush lowered their target price on Viridian Therapeutics from $37.00 to $31.00 and set an “outperform” rating for the company in a research note on Wednesday, April 8th. Finally, Weiss Ratings reissued a “sell (d-)” rating on shares of Viridian Therapeutics in a research note on Monday, April 20th. Twelve analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, Viridian Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $36.14.

Viridian Therapeutics Profile

Viridian Therapeutics, Inc (NASDAQ: VRDN) is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted antibody therapeutics for patients suffering from rare and serious diseases. The company’s lead program, VRDN-001, is a fully human monoclonal antibody that antagonizes the insulin-like growth factor-1 receptor (IGF-1R), with an initial focus on thyroid eye disease (TED). By selectively inhibiting IGF-1R signaling, VRDN-001 aims to reduce inflammation and tissue remodeling associated with TED and related disorders.

In addition to VRDN-001, Viridian is advancing a second antibody program, VRDN-002, which targets complement-mediated pathways implicated in autoimmune and inflammatory diseases.